ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence Eichenfield, MD, FAAD, as chair of its Scientific Advisory Board, comprising experts in dermatology and allergic disease from the United States, Canada, Europe, and Asia. Dr Eric Simpson, MD, MCR, was also appointed as a board member.

For more information, please refer to the press release.